All In Biotech

Drug Trial Radar · NCT06063057

Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial

Inactivated Bivalent Enterovirus Vaccine Phase I/II Clinical Trial: Open-Label Observation in Healthy Adults and Children, and Randomized, Double-Blind, Controlled Clinical Trial in Children

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 744 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

744

Actual

Start

Sep 20, 2023

Primary completion

Dec 19, 2025

Study completion Mar 10, 2026

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Oct 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Phase I clinical trial is divided into two parts. The first part uses an open-label design, while the second part uses a randomized, double-blind, and controlled design. The goal of this clinical trial is to evaluate the tolerability and safety of a bivalent (EV71/CA16, Enterovirus 71/Coxsackievirus A16) inactivated enterovirus vaccine (Vero cell) developed by Sinovac. The vaccine will be administered to healthy adults, children aged 6 to 12 years, and children aged 6 to 71 months. The Phase II clinical trial will also use a randomized, double-blind, and controlled design to evaluate the safety and immunogenicity of the same bivalent inactivated enterovirus vaccine (Vero cell) developed by Sinovac. This trial will involve healthy children aged 6 to 71 months.

Conditions

  • Hand, Foot and Mouth Disease
  • Herpangina

Interventions

  • low dose Bivalent Enterovirus Vaccine (Vero Cell), InactivatedBiological

    Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml

  • medium dose Bivalent Enterovirus Vaccine (Vero Cell), InactivatedBiological

    Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml

  • high dose Bivalent Enterovirus Vaccine (Vero Cell), InactivatedBiological

    Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml

  • Enterovirus type EV71 vaccine (Vero cell), InactivatedBiological

    Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ⅰ: Based on adverse events, evaluate the safety of the trial vaccine among participants in different age groupsTime frame: 30 days
  2. Phase Ⅱ: Evaluate the immunogenicity of the trial vaccine in the target population.Time frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dayao County Center for Disease Control and Prevention

    Chuxiong, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.